Compare Novo Nordisk A/S (NVO) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TKO Group Holdings Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while TKO Group Holdings Inc trades at $178.01 (market cap $13.28B). The key difference: Novo Nordisk A/S is far larger — about 12.4× TKO Group Holdings Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and TKO Group Holdings Inc for 30 Days on average.
| NVO | TKO | |
|---|---|---|
Market Cap | $165.31B | $13.28B |
Volume | 11,432,838 | 857,653 |
Sector | Health | Media |
52-Week High | $63.98 | $224.96 |
52-Week Low | $35.29 | $175.58 |
Typical Hold Time | 116 Days | 30 Days |
Enterprise Value | $179.56B | $17.64B |
Dividend Yield | 4.71% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
TKO trades at $178.01, down 0.35% on the day, near its 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings history, including a Q2 2026 EPS miss. Revenue grew to $5.3B in 2026 with a net profit margin of 4.32%. A quarterly dividend of $0.79 is scheduled for payment on September 30, 2026.
Wall Street maintains a strong buy consensus (89% buy ratings) with a $227 price target, suggesting significant upside. Key risks include earnings volatility and competitive pressures in sports entertainment. Positive catalysts are media rights deals and live event momentum, but the stock faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
